30 March 2015

McCann FitzGerald advising Horizon Pharma on proposed $1.1 billion acquisition of Hyperion Therapeutics, Inc.

We are acting as Irish counsel to Horizon Pharma plc in relation to its proposed acquisition of Hyperion Therapeutics, Inc. for $46.00 per Share or $1.1 billion in cash.

Key contacts